Epidemiology
Your Organizational Guidance
ebpracticenet urges you to prioritize the following organizational guidance:
Diagnose en aanpak van gonorroePublished by: KCELast published: 2023Diagnostic et prise en charge de la gonorrhéePublished by: KCELast published: 2023Gonorrhea is the second most commonly reported communicable disease in the US, and the number of cases has shown a sustained increase over the past 10 years.[3] During 2021 and 2022, however, rates of reported gonorrhea decreased among both men (5.4%) and women (14.5%).[3] From 2022 to 2023, rates of infection continued to decrease, with the decrease more pronounced among women (14.1%) than men (3.4%).[3] These years coincide with the COVID-19 pandemic, which introduced uncertainty and difficulty in interpreting sexually transmitted infection surveillance data.[3] In 2023, the gonorrhea rate in the US was 179.5 cases per 100,000.[3] The southern US continues to have the highest rates in the country. Rates continue to be highest among certain groups, such as men who have sex with men or black and African American black people. Rates also continue to be higher in men than in women. The highest rates in men and women are seen in the 20 to 24 years age group.[3]
High rates of antimicrobial resistance to penicillin, tetracycline, and fluoroquinolones have been reported from the Gonococcal Isolate Surveillance Project, and there is concern about the potential of reduced susceptibility to extended-spectrum cephalosporins and macrolides.[4] Rare isolates have also been found with reduced susceptibility to cephalosporins and azithromycin, which has led to increased vigilance for antimicrobial resistance and updated treatment guidance.
Use of this content is subject to our disclaimer